The Theravance Biopharma Inc. (TBPH) Given Average Rating of “Hold” by Brokerages

The Theravance Biopharma Inc. (TBPH) Given Average Rating of “Hold” by Brokerages

Theravance Biopharma Inc. (NASDAQ:TBPH) has received an average rating of “Hold” from the nine ratings firms that are presently covering the firm. Three equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $36.67.

Several equities analysts recently commented on TBPH shares. Needham & Company LLC started coverage on shares of Theravance Biopharma in a research note on Wednesday, December 21st. They set a “buy” rating and a $40.00 target price for the company. Zacks Investment Research upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research note on Tuesday, December 13th. Leerink Swann reiterated a “buy” rating and set a $33.00 target price on shares of Theravance Biopharma in a research note on Wednesday, November 9th. Piper Jaffray Cos. started coverage on shares of Theravance Biopharma in a research note on Thursday, November 3rd. They set an “overweight” rating and a $42.00 target price for the company. Finally, TheStreet cut shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, November 17th.

Large investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA boosted its stake in shares of Theravance Biopharma by 110.2% in the third quarter. BNP Paribas Arbitrage SA now owns 3,008 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,577 shares during the period. Strs Ohio purchased a new stake in shares of Theravance Biopharma during the third quarter worth about $134,000. Teacher Retirement System of Texas boosted its stake in shares of Theravance Biopharma by 40.2% in the second quarter. Teacher Retirement System of Texas now owns 4,887 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 1,401 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Theravance Biopharma by 3.3% in the second quarter. PNC Financial Services Group Inc. now owns 5,992 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 192 shares during the period. Finally, Clinton Group Inc. purchased a new stake in shares of Theravance Biopharma during the third quarter worth about $217,000. Institutional investors and hedge funds own 66.29% of the company’s stock.

Theravance Biopharma (NASDAQ:TBPH) opened at 31.98 on Thursday. Theravance Biopharma has a 1-year low of $13.59 and a 1-year high of $38.92. The firm’s 50-day moving average is $31.45 and its 200-day moving average is $29.75. The firm’s market capitalization is $1.66 billion.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Related posts

Leave a Comment